Writing

Molecular gatekeepers of cardiomyocyte proliferation, in vivo reprogramming of cardiac fibroblasts, and cell cycle arrest in cardiomyocytes · three papers unpacked with clinical relevance and limitations.

Scalable cardiomyocyte production in bioreactors, engineered heart muscle allografts in primates and a first human case (BioVAT-HF), and fibroblast reprogramming progress in JACC.

A broad-spectrum week: stem cell technology for cardiac regeneration, post-MI repair strategies across cell therapy, in vivo reprogramming and tissue engineering, and fibroblast conversion into cardiomyocytes.

Primitive macrophage secretome driving cardiomyocyte proliferation, multilineage cardiac co-differentiation systems, and maturation of cardiac organoids for functional disease modeling.

Extracellular vesicles as cell-free cardiac therapy, metabolic control of cardiomyocyte regenerative capacity, and a documented human case of near-complete cardiac recovery in a neonate.

The silent epidemic of hypertension and high cholesterol in children and young adults · and why cardiovascular research continues to underrepresent the under-40 demographic at its own peril.